Laura Capelli et al., No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC). Scientific Reports

Laura Capelli1, Andrea Casadei Gardini2, Emanuela Scarpi3, Giovanni Luca Frassineti2, Luca Saragoni4, Maurizio Puccetti5, Mario Scartozzi6, Massimo Giannini7, Stefano Tamberi8, Jody Corbelli8 & Paola Ulivi1

1Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
2Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
3Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
4Pathology Unit, Morgagni-Pierantoni Hospital, Forlì, Italy
5Pathology Unit, S.Maria delle Croci Hospital, Ravenna, Italy
6Medical Oncology, University Hospital, University of Cagliari, Cagliari, Italy
7Radiotherapy Unit, Macerata Hospital, Macerata, Italy
8Medical Oncology Unit, Degli Infermi Hospital, Faenza, Italy

Abstract:

Epidermal growth factor receptor (EGFR) is usually expressed in squamous cell anal carcinoma (SCAC) and anti-EGFR agents could represent a valid treatment strategy, also considering that KRAS and BRAF mutations are rare events in this type of cancer. However, no data are available on NRAS status in SCAC. In this study we analyzed NRAS status (exons 2–4) by Pyrosequencing in a case series of 50 SCAC patients previously characterized in our laboratory for KRAS, BRAF, PIK3CA mutations and HPV and HIV infections. We found no mutation in NRAS gene. These results confirm that since the principal anti-EGFR resistance mechanisms are almost absent in SCAC, anti-EGFR agents should be considered for the treatment of this type of cancer.

Read the complete publication at this link

Authors
Products
Request information

Please insert your email address below, we will contact you soon.


I consent to privacy



2017-08-08T12:52:59+00:00